JP2021523127A - 限られたｔ細胞炎症反応で標的抗体産生を促進する人工的な無差別ｔヘルパー細胞エピトープ - Google Patents

限られたｔ細胞炎症反応で標的抗体産生を促進する人工的な無差別ｔヘルパー細胞エピトープ Download PDF

Info

Publication number
JP2021523127A
JP2021523127A JP2020561828A JP2020561828A JP2021523127A JP 2021523127 A JP2021523127 A JP 2021523127A JP 2020561828 A JP2020561828 A JP 2020561828A JP 2020561828 A JP2020561828 A JP 2020561828A JP 2021523127 A JP2021523127 A JP 2021523127A
Authority
JP
Japan
Prior art keywords
epitope
peptide
cell epitope
antigenic site
target antigenic
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2020561828A
Other languages
English (en)
Japanese (ja)
Other versions
JP2021523127A5 (enExample
Inventor
イ ワン、チャン
イ ワン、チャン
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Ubi Ip Holdings
Original Assignee
Ubi Ip Holdings
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ubi Ip Holdings filed Critical Ubi Ip Holdings
Publication of JP2021523127A publication Critical patent/JP2021523127A/ja
Publication of JP2021523127A5 publication Critical patent/JP2021523127A5/ja
Priority to JP2024060650A priority Critical patent/JP2024095743A/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0007—Nervous system antigens; Prions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505—Inorganic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55516—Proteins; Peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55544—Bacterial toxins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55561—CpG containing adjuvants; Oligonucleotide containing adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A61K2039/572—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 cytotoxic response
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/64—Medicinal preparations containing antigens or antibodies characterised by the architecture of the carrier-antigen complex, e.g. repetition of carrier-antigen units
    • A61K2039/645—Dendrimers; Multiple antigen peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2730/00—Reverse transcribing DNA viruses
    • C12N2730/00011—Details
    • C12N2730/10011—Hepadnaviridae
    • C12N2730/10111—Orthohepadnavirus, e.g. hepatitis B virus
    • C12N2730/10134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18411—Morbillivirus, e.g. Measles virus, canine distemper
    • C12N2760/18434—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Virology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Hospice & Palliative Care (AREA)
  • Biotechnology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Psychiatry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
JP2020561828A 2018-05-04 2019-05-03 限られたｔ細胞炎症反応で標的抗体産生を促進する人工的な無差別ｔヘルパー細胞エピトープ Pending JP2021523127A (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2024060650A JP2024095743A (ja) 2018-05-04 2024-04-04 限られたｔ細胞炎症反応で標的抗体産生を促進する人工的な無差別ｔヘルパー細胞エピトープ

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862667123P 2018-05-04 2018-05-04
US62/667,123 2018-05-04
PCT/US2019/030649 WO2019213555A1 (en) 2018-05-04 2019-05-03 Artificial promiscuous t helper cell epitopes that facilitate targeted antibody production with limited t cell inflammatory response

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2024060650A Division JP2024095743A (ja) 2018-05-04 2024-04-04 限られたｔ細胞炎症反応で標的抗体産生を促進する人工的な無差別ｔヘルパー細胞エピトープ

Publications (2)

Publication Number Publication Date
JP2021523127A true JP2021523127A (ja) 2021-09-02
JP2021523127A5 JP2021523127A5 (enExample) 2022-02-10

Family

ID=68386088

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2020561828A Pending JP2021523127A (ja) 2018-05-04 2019-05-03 限られたｔ細胞炎症反応で標的抗体産生を促進する人工的な無差別ｔヘルパー細胞エピトープ
JP2024060650A Pending JP2024095743A (ja) 2018-05-04 2024-04-04 限られたｔ細胞炎症反応で標的抗体産生を促進する人工的な無差別ｔヘルパー細胞エピトープ

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2024060650A Pending JP2024095743A (ja) 2018-05-04 2024-04-04 限られたｔ細胞炎症反応で標的抗体産生を促進する人工的な無差別ｔヘルパー細胞エピトープ

Country Status (12)

Country Link
US (2) US20220023400A1 (enExample)
EP (1) EP3790581A4 (enExample)
JP (2) JP2021523127A (enExample)
KR (1) KR20210010873A (enExample)
CN (1) CN112218655A (enExample)
AU (1) AU2019262609A1 (enExample)
BR (1) BR112020022443A2 (enExample)
CA (1) CA3099296A1 (enExample)
MX (1) MX2020011733A (enExample)
SG (1) SG11202010942WA (enExample)
TW (1) TWI754817B (enExample)
WO (1) WO2019213555A1 (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2024026558A (ja) * 2019-05-31 2024-02-28 株式会社半導体エネルギー研究所 半導体装置の作製方法

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN112876570B (zh) * 2021-02-09 2022-07-26 中国农业科学院生物技术研究所 非洲猪瘟病毒疫苗及其制备方法
CA3261968A1 (en) * 2022-07-14 2024-01-18 Vaxxinity, Inc. IMMUNOGENEOUS TAU PEPTIDE CONSTRUCTIONS
CN118812726B (zh) * 2024-06-26 2025-05-16 西北民族大学 脑心肌炎多抗原表位重组蛋白及其在制备脑心肌炎疫苗中的应用

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2002518463A (ja) * 1998-06-20 2002-06-25 ユナイティド バイオメディカル インコーポレイティド 合成ペプチド免疫原のための免疫刺激因子としての人工的ｔヘルパー細胞エピトープ
JP2003504302A (ja) * 1998-06-20 2003-02-04 ユナイティド バイオメディカル インコーポレイティド 合成ペプチド免疫原のための免疫刺激因子としての人工的ｔヘルパー細胞エピトープ
JP2016513638A (ja) * 2013-03-15 2016-05-16 ユナイテッド・バイオメディカル・インコーポレーテッドＵｎｉｔｅｄ Ｂｉｏｍｅｄｉｃａｌ Ｉｎｃｏｒｐｏｒａｔｅｄ アルツハイマー型認知症の予防用及び免疫療法用ペプチドワクチン

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20140088020A1 (en) * 1999-08-30 2014-03-27 David S Terman Composition and Methods for Treatment of Cancer
US6906169B2 (en) * 2001-05-25 2005-06-14 United Biomedical, Inc. Immunogenic peptide composition comprising measles virus Fprotein Thelper cell epitope (MUFThl-16) and N-terminus of β-amyloid peptide
DE60336848D1 (de) * 2002-09-12 2011-06-01 Univ California Immunogene und entsprechende antikörper, die spezifisch sind für häufige hochmolekulare aggregations-zwischenprodukte von amyloiden aus proteinen unterschiedlicher sequenz
JP5863582B2 (ja) * 2012-07-02 2016-02-16 東京エレクトロン株式会社 プラズマ処理装置、及び温度制御方法
CN105992587A (zh) * 2013-02-18 2016-10-05 春堤制药公司 作为疫苗佐剂和治疗试剂的短寡核苷酸的设计
US10450352B2 (en) * 2016-03-23 2019-10-22 Board Of Regents, The University Of Texas System Engineered polypeptides for antigen delivery

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2002518463A (ja) * 1998-06-20 2002-06-25 ユナイティド バイオメディカル インコーポレイティド 合成ペプチド免疫原のための免疫刺激因子としての人工的ｔヘルパー細胞エピトープ
JP2003504302A (ja) * 1998-06-20 2003-02-04 ユナイティド バイオメディカル インコーポレイティド 合成ペプチド免疫原のための免疫刺激因子としての人工的ｔヘルパー細胞エピトープ
JP2016513638A (ja) * 2013-03-15 2016-05-16 ユナイテッド・バイオメディカル・インコーポレーテッドＵｎｉｔｅｄ Ｂｉｏｍｅｄｉｃａｌ Ｉｎｃｏｒｐｏｒａｔｅｄ アルツハイマー型認知症の予防用及び免疫療法用ペプチドワクチン

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2024026558A (ja) * 2019-05-31 2024-02-28 株式会社半導体エネルギー研究所 半導体装置の作製方法

Also Published As

Publication number Publication date
SG11202010942WA (en) 2020-12-30
EP3790581A1 (en) 2021-03-17
EP3790581A4 (en) 2022-06-22
US20220023400A1 (en) 2022-01-27
WO2019213555A1 (en) 2019-11-07
MX2020011733A (es) 2021-01-15
CA3099296A1 (en) 2019-11-07
TWI754817B (zh) 2022-02-11
JP2024095743A (ja) 2024-07-10
AU2019262609A1 (en) 2020-12-03
KR20210010873A (ko) 2021-01-28
TW201946649A (zh) 2019-12-16
CN112218655A (zh) 2021-01-12
BR112020022443A2 (pt) 2021-02-09
US20250262286A1 (en) 2025-08-21

Similar Documents

Publication Publication Date Title
JP7555598B2 (ja) 合成ペプチド免疫原のための免疫刺激薬としての人工無差別ｔヘルパー細胞エピトープ
US20250262286A1 (en) Artificial promiscuous t helper cell epitopes that facilitate targeted antibody production with limited t cell inflammatory response
AU764961B2 (en) Artificial T helper cell epitopes as immune stimulators for synthetic peptide immunogens including immunogenic LHRH peptides
CN113574073B (zh) 针对降钙素基因相关肽(cgrp)的肽免疫原及其用于预防和治疗偏头痛的制剂
AU2013381835A1 (en) Peptide vaccine for prevention and immunotherapy of dementia of the Alzheimer's type
TW202028223A (zh) 針對源自c9orf72二肽重複蛋白的胜肽免疫原結構
JP5901084B2 (ja) ペプチドアジュバント
TWI823051B (zh) 針對垂體腺苷酸環化酶激活胜肽的胜肽免疫原及其預防和治療偏頭痛的製劑
TW202142551A (zh) 針對pcsk9胜肽免疫原及其預防和治療pcsk9介導疾病的製劑
HK40045220A (en) Artificial promiscuous t helper cell epitopes that facilitate targeted antibody production with limited t cell inflammatory response
RU2839585C2 (ru) Искусственные неизбирательные эпитопы клеток т-хелперов как иммунные стимуляторы для синтетических пептидных иммуногенов
EP4554618A2 (en) Tau peptide immunogen constructs
TW202541836A (zh) 肽免疫原組合物及其用途

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220202

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20220202

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20230228

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20230523

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20230728

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230830

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20231205